PL2086932T3 - Podstawione związki arylo-indoli i ich metabolity kynurenino/kynuramino podobne jako środki lecznicze - Google Patents

Podstawione związki arylo-indoli i ich metabolity kynurenino/kynuramino podobne jako środki lecznicze

Info

Publication number
PL2086932T3
PL2086932T3 PL07859335T PL07859335T PL2086932T3 PL 2086932 T3 PL2086932 T3 PL 2086932T3 PL 07859335 T PL07859335 T PL 07859335T PL 07859335 T PL07859335 T PL 07859335T PL 2086932 T3 PL2086932 T3 PL 2086932T3
Authority
PL
Poland
Prior art keywords
kynuramine
kynurenine
metabolites
substituted aryl
therapeutic agents
Prior art date
Application number
PL07859335T
Other languages
English (en)
Inventor
Tal Peleg-Shulman
Moshe Laudon
Dvorah Daily
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of PL2086932T3 publication Critical patent/PL2086932T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL07859335T 2006-10-03 2007-10-03 Podstawione związki arylo-indoli i ich metabolity kynurenino/kynuramino podobne jako środki lecznicze PL2086932T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84864206P 2006-10-03 2006-10-03
EP07859335.7A EP2086932B1 (en) 2006-10-03 2007-10-03 Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
PCT/IB2007/004306 WO2008041140A2 (en) 2006-10-03 2007-10-03 Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents

Publications (1)

Publication Number Publication Date
PL2086932T3 true PL2086932T3 (pl) 2015-02-27

Family

ID=39271279

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07859335T PL2086932T3 (pl) 2006-10-03 2007-10-03 Podstawione związki arylo-indoli i ich metabolity kynurenino/kynuramino podobne jako środki lecznicze

Country Status (13)

Country Link
US (3) US7622495B2 (pl)
EP (2) EP2086932B1 (pl)
JP (1) JP5426386B2 (pl)
CN (1) CN101528689B (pl)
AR (1) AR063128A1 (pl)
CL (1) CL2007002858A1 (pl)
DK (1) DK2086932T3 (pl)
ES (1) ES2523026T3 (pl)
PL (1) PL2086932T3 (pl)
PT (1) PT2086932E (pl)
SI (1) SI2086932T1 (pl)
TW (1) TWI407954B (pl)
WO (1) WO2008041140A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642598B2 (en) 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MX2010013393A (es) 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9580398B2 (en) 2012-04-02 2017-02-28 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
WO2014152752A1 (en) * 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
JP6664814B2 (ja) * 2014-08-18 2020-03-13 国立大学法人大阪大学 新規2−アミノベンゾイル誘導体
PE20171259A1 (es) * 2014-12-19 2017-08-28 Glaxosmithkline Ip Dev Ltd Compuestos
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
CN106362155A (zh) * 2016-10-08 2017-02-01 无锡汉强医药科技有限公司 Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用
CN106995828B (zh) * 2017-02-04 2020-10-09 中国科学院成都生物研究所 利用喜树悬浮细胞生产n1-乙酰犬尿胺的方法
WO2018216705A1 (ja) * 2017-05-23 2018-11-29 国立大学法人京都大学 神経変性疾患の予防及び/又は治療剤
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870162A (en) * 1954-04-28 1959-01-20 Upjohn Co Production of certain tryptamines and compounds produced in the process
JPS5336455B2 (pl) 1973-02-03 1978-10-03
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
JP2000007626A (ja) 1998-06-25 2000-01-11 Taisho Pharmaceut Co Ltd N−置換ニトロアニリン誘導体
IL138825A (en) 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
HRPK20040271B3 (en) * 2001-09-27 2006-02-28 F. Hoffmann - La Roche Ag Indole derivatives as cox ii inhibitors
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
IL156669A0 (en) 2003-06-26 2004-01-04 Neurim Pharma 1991 2-aminobenzoyl derivatives
SI1809622T1 (sl) 2004-09-22 2010-11-30 Janssen Pharmaceutica Nv Inhibitorji interakcije med MDM in P

Also Published As

Publication number Publication date
PT2086932E (pt) 2014-11-10
JP5426386B2 (ja) 2014-02-26
AR063128A1 (es) 2008-12-30
US8003702B2 (en) 2011-08-23
WO2008041140A3 (en) 2008-08-14
US20100048663A1 (en) 2010-02-25
TW200824684A (en) 2008-06-16
EP2086932A2 (en) 2009-08-12
JP2010505816A (ja) 2010-02-25
US7622495B2 (en) 2009-11-24
SI2086932T1 (sl) 2014-12-31
DK2086932T3 (da) 2014-11-10
US20110319494A1 (en) 2011-12-29
EP2086932B1 (en) 2014-08-27
CL2007002858A1 (es) 2008-05-16
US8236858B2 (en) 2012-08-07
ES2523026T3 (es) 2014-11-20
HK1133886A1 (en) 2010-04-09
EP2664615A1 (en) 2013-11-20
WO2008041140A2 (en) 2008-04-10
US20080132559A1 (en) 2008-06-05
CN101528689A (zh) 2009-09-09
TWI407954B (zh) 2013-09-11
CN101528689B (zh) 2013-04-24
WO2008041140A8 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
SI2086932T1 (sl) Substituirane aril-indol spojine in kinurenin/kinuramin- podobni metaboliti kot terapevtska sredstva
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
GB0625659D0 (en) Therapeutic compounds and their use
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
IL186616A (en) Spyro-oxa-indoles and their use as drugs
GB0609492D0 (en) Therapeutic agents
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
GB0803018D0 (en) Therapeutic compounds and their use
GB0601962D0 (en) Therapeutic agents
GB0804685D0 (en) Therapeutic compounds and their use
GB0724251D0 (en) Therapeutic compounds and their use
HU0500170D0 (en) New compounds with therapeutic effects
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
GB0616214D0 (en) Therapeutic Agents
GB0611152D0 (en) Therapeutic agents
GB0812913D0 (en) Therapeutic compounds and their use
GB0620059D0 (en) Therapeutic agents
GB0514738D0 (en) Therapeutic agents
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB0620818D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
GB0802128D0 (en) Therapeutic compounds and their use